JONATHAN SLONIN - 02 Jan 2025 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
02 Jan 2025
Net transactions value
-$22,974
Form type
4
Filing time
06 Jan 2025, 18:23:10 UTC
Previous filing
02 Aug 2024
Next filing
04 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Tax liability $6,800 -371 -0.39% $18.33 94,323 02 Jan 2025 Direct F1, F2
transaction PCRX Common Stock Sale $16,174 -879 -0.93% $18.40 93,444 06 Jan 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2 Includes 386.765 shares of common stock acquired under the issuer's employee stock purchase plan in December 2024.
F3 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.